CG Oncology, Inc.

CGON

$56.67

Name : CG Oncology, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $4,998,433,792.00

EPSttm : -2.34

CG Oncology, Inc.

$56.67

4.17%

$2.27

CGON — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

15.97

Margin Of Safety %

Put/Call OI Ratio

0.35

EPS Next Q Diff

0.04

EPS Last/This Y

-0.58

EPS This/Next Y

-0.12

Price

56.63

Target Price

90.29

Analyst Recom

1.12

Performance Q

-9.76

Upside

-153.7%

Beta

0.45

Ticker: CGON

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-05-11	CGON	69.24	0.36	0.01	50203
2026-05-12	CGON	72.1	0.36	0.01	50247
2026-05-13	CGON	74.03	0.36	0.12	50250
2026-05-14	CGON	69.8	0.36	0.29	50221
2026-05-15	CGON	66.89	0.37	0.27	50268
2026-05-18	CGON	62.93	0.39	0.03	43707
2026-05-19	CGON	63.34	0.39	0.62	43879
2026-05-20	CGON	64.79	0.39	0.46	43965
2026-05-21	CGON	64.54	0.39	0.22	44038
2026-05-22	CGON	64.16	0.39	0.20	45966
2026-05-26	CGON	61.86	0.39	0.46	45962
2026-05-27	CGON	60.81	0.34	0.07	29454
2026-05-28	CGON	60.69	0.39	0.01	46338
2026-05-29	CGON	62.24	0.39	2.92	46362
2026-06-02	CGON	55.51	0.40	0.13	46629
2026-06-03	CGON	54.42	0.40	0.71	46675
2026-06-04	CGON	56.13	0.40	0.00	47121
2026-06-05	CGON	53.68	0.40	0.04	47144
2026-06-08	CGON	54.36	0.37	0.19	50709
2026-06-09	CGON	56.68	0.35	0.00	53653
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-05-11	CGON	69.28	-20.0	-35.4	-2.39
2026-05-12	CGON	72.11	-19.8	-23.7	-2.58
2026-05-13	CGON	74.00	-19.8	-80.8	-2.58
2026-05-14	CGON	69.54	-17.6	-51.1	-2.62
2026-05-15	CGON	66.92	-17.6	-58.7	-2.62
2026-05-18	CGON	62.90	-17.6	-50.8	-2.62
2026-05-19	CGON	63.29	-17.6	-74.0	-2.62
2026-05-20	CGON	64.80	-17.6	-80.3	-2.62
2026-05-21	CGON	64.59	-17.6	-70.9	-2.62
2026-05-22	CGON	64.15	-18.8	-69.5	-2.66
2026-05-26	CGON	61.81	-18.8	-58.5	-2.66
2026-05-27	CGON	60.80	-18.8	-66.1	-2.66
2026-05-28	CGON	60.69	-18.8	-71.3	-2.66
2026-05-29	CGON	62.28	-18.8	-81.2	-2.66
2026-06-01	CGON	59.28	-18.8	-54.6	-2.66
2026-06-02	CGON	55.53	-18.8	-49.4	-2.66
2026-06-03	CGON	54.35	-18.8	-64.3	-2.66
2026-06-04	CGON	56.09	-18.8	-83.6	-2.66
2026-06-05	CGON	53.72	-18.8	-56.4	-2.66
2026-06-08	CGON	54.37	-18.8	-76.4	-2.66
2026-06-09	CGON	56.63	-18.8	-87.2	-2.66
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-05-11	CGON	-0.10	5.68	17.02
2026-05-12	CGON	-0.10	5.68	16.47
2026-05-13	CGON	-0.10	5.68	15.76
2026-05-14	CGON	-0.10	5.68	15.76
2026-05-15	CGON	-0.10	5.68	15.76
2026-05-18	CGON	-0.10	5.78	15.76
2026-05-19	CGON	-0.10	5.78	15.76
2026-05-20	CGON	-0.10	5.78	15.76
2026-05-21	CGON	-0.10	5.78	15.60
2026-05-22	CGON	-0.10	5.78	15.60
2026-05-26	CGON	-0.10	1.23	15.60
2026-05-27	CGON	-0.10	1.23	15.60
2026-05-28	CGON	-0.10	1.23	14.72
2026-05-29	CGON	-0.11	1.23	14.72
2026-06-02	CGON	-0.09	2.17	15.97
2026-06-03	CGON	-0.09	2.17	15.97
2026-06-04	CGON	-0.09	2.17	15.97
2026-06-05	CGON	-0.09	2.17	15.97
2026-06-08	CGON	-0.10	1.85	15.97
2026-06-09	CGON	-0.10	1.85	15.97
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.71

Avg. EPS Est. Current Quarter

-0.64

Avg. EPS Est. Next Quarter

-0.67

Insider Transactions

-0.1

Institutional Transactions

1.85

Beta

0.45

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

90.29

P/E

Forward P/E

PEG

P/S

985.88

P/B

4.57

P/Free Cash Flow

EPS

-2.34

Average EPS Est. Cur. Y

-2.66

EPS Next Y. (Est.)

-2.78

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-3682.61

Relative Volume

1.02

Return on Equity vs Sector %

-44.6

Return on Equity vs Industry %

-28.4

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.26

EBIT Estimation

-87.2

◆ CGON Healthcare

$56.67

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

8/20

Pullback

17/25

Volume

4/15

Valuation

10/20

TP/AR

6/10

Options

5/10

RSI

38.9

Range 1M

10.9%

Sup Dist

6.1%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

8/25

Growth

7/30

Estimates

7/20

Inst/Vol

5/15

Options

7/10

EPS Yr

-31.9%

EPS NY

-3.4%

52W%

61.7%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +59.3% upside

Quality

2/30

Valuation

10/30

Growth

4/25

Stability

9/10

LT Trend

2/5

Upside

+59.3%

Quality

CG Oncology, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 142

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.

CGON

Latest News

—

Caricamento notizie per CGON…

stock quote shares CGON – Cg Oncology Inc Stock Price stock today

news today CGON – Cg Oncology Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch CGON – Cg Oncology Inc yahoo finance google finance

stock history CGON – Cg Oncology Inc invest stock market

stock prices CGON premarket after hours

ticker CGON fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: CGON

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y